NCT03079882

VisR Ultrasound for Noninvasively Monitoring Renal Allograft Health

Completed Last updated 24 June 2021

What this trial tests

trial in Renal Transplant Failure in 65 participants. Completed in 28 February 2021.

Timeline

16 June 2016

Primary endpoint
28 February 2021

28 February 2021

Quick facts

Lead sponsor	University of North Carolina, Chapel Hill
Status	Completed
Study type	OBSERVATIONAL
Enrollment	65
Start date	16 June 2016
Primary completion	28 February 2021
Estimated completion	28 February 2021
Sites	1 location across United States

Conditions studied

• Renal Transplant Failure — all drugs for Renal Transplant Failure →

Sponsor

University of North Carolina, Chapel Hill

Who can join

18 and older, any sex, with Renal Transplant Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ten percent of American adults, more than 20 million people, have chronic kidney disease, which in the advanced state of end stage renal disease is most desirably and cost-effectively treated by kidney transplantation. However, 20-30% of transplanted kidneys fail in living recipients by 10 years, owing largely to insufficient monitoring methods. The goal of the proposed research is to improve noninvasive kidney transplant monitoring using a new ultrasound-based imaging method called Viscoelastic Response (VisR) ultrasound.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Mechanical Anisotropy Assessment in Kidney Cortex Using ARFI Peak Displacement: Preclinical Validation and Pilot In Vivo Clinical Results in Kidney Allografts.
   Hossain MM, Detwiler RK, Chang EH, Caughey MC, et al · · 2019 · cited 12× · PMID 30106723 · DOI 10.1109/tuffc.2018.2865203